PMID- 38030166
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20231216
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 12
DP  - 2023 Dec
TI  - Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from 
      a Maximum Care Center.
PG  - 5589-5596
LID - 10.21873/anticanres.16761 [doi]
AB  - BACKGROUND/AIM: Systemic treatment for metastatic colorectal cancer (CRC) 
      includes chemotherapy in combination with a targeted antibody. Novel targeted 
      therapies and immunotherapies are introduced for specific molecular subgroups. 
      Prognostic relevant determinants are still under investigation. PATIENTS AND 
      METHODS: Systemic therapies of an unselected patient cohort with metastatic CRC 
      were retrospectively analyzed. Treatment outcome was evaluated according to 
      time-to-next-treatment (TTNT) and frequency of conversion surgery and compared 
      between subgroups stratified by primary tumor side, molecular profile, sex and 
      age, and metastases sites. RESULTS: More than 50% of patients with locally 
      advanced or metastatic CRC underwent secondary resection after first-line 
      systemic therapy. Rectum carcinoma had the best prognosis under 
      anti-EGFR-antibody treatment. Female patients had a worse prognosis than male 
      patients in late disease stage. Young patients demonstrated poor response to 
      systemic therapy, but a high rate of conversion surgeries. Conversely, elderly 
      patients benefited from systemic therapy but underwent surgery less frequently. 
      Liver and lung metastases had a worse prognosis than other metastases sites, 
      whereas lung metastases were more likely to be resected than liver metastases in 
      early disease stage. CONCLUSION: Patient age, sex, primary tumor localization, 
      and metastatic sites are prognostic factors that could guide future treatment 
      decisions for the therapy of metastatic CRC.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zhang, Xin-Wen
AU  - Zhang XW
AD  - Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases 
      (NCT), University Hospital Heidelberg, INF 460, Heidelberg, Germany.
AD  - Translational Immunotherapy (D240), German Cancer Research Center (DKFZ), INF 
      280, Heidelberg, Germany.
FAU - Mohr, Jutta
AU  - Mohr J
AD  - Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, 
      Heidelberg University Hospital, INF 410, Heidelberg, Germany.
FAU - Halama, Niels
AU  - Halama N
AD  - Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases 
      (NCT), University Hospital Heidelberg, INF 460, Heidelberg, Germany; 
      niels.halama@nct-heidelberg.de.
AD  - Translational Immunotherapy (D240), German Cancer Research Center (DKFZ), INF 
      280, Heidelberg, Germany.
AD  - BioQuant, Faculty of Biosciences, Heidelberg University, INF 267, Heidelberg, 
      Germany.
FAU - Koschny, Ronald
AU  - Koschny R
AD  - Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, 
      Heidelberg University Hospital, INF 410, Heidelberg, Germany; 
      ronald.koschny@med.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Aged
MH  - Retrospective Studies
MH  - *Colorectal Neoplasms/pathology
MH  - *Colonic Neoplasms/pathology
MH  - *Rectal Neoplasms/therapy/pathology
MH  - Prognosis
MH  - *Lung Neoplasms/drug therapy
MH  - *Liver Neoplasms/secondary
OTO - NOTNLM
OT  - Colorectal cancer
OT  - chemotherapy
OT  - colorectal liver metastases
OT  - metastases
OT  - secondary surgery
OT  - time-to-next-treatment
OT  - tumor sidedness
EDAT- 2023/11/30 00:41
MHDA- 2023/12/01 06:43
CRDT- 2023/11/29 20:33
PHST- 2023/10/09 00:00 [received]
PHST- 2023/11/10 00:00 [revised]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2023/12/01 06:43 [medline]
PHST- 2023/11/30 00:41 [pubmed]
PHST- 2023/11/29 20:33 [entrez]
AID - 43/12/5589 [pii]
AID - 10.21873/anticanres.16761 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Dec;43(12):5589-5596. doi: 10.21873/anticanres.16761.